I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $318.3M |
||||
|
Company | Location | Date | Amt. (M) | Details |
AGY Therapeutics Inc. | South San Francisco | 5/7 | $13 | AGY raised $13M in its second round; investors included Alta Partners, GIMV Venture Capital, Forward Ventures, Jafco Co., Lombard Odier & Cie and Novartis Venture Fund |
Aptus Genomics Inc. | Rockville, Md. | 5/14 | $6.2 | Aptus closed its first round, raising $6.2M; Emerging Technology Partners LLC led the round and The Grosvenor Funds LLC and VitalBio LLC participated |
Astex Technology Ltd. | Cambridge, UK | 5/4 | #22.7 (US$32.5) | Astex raised US$32.5M in its first round; investors included Advent International, Alta Partners, GIMV NV, Abingworth Management Ltd. and Oxford Bioscience Partners |
BioMimetic Pharmaceuticals | Nashville, Tenn. | 5/24 | $6.5 | BioMimetic completed a $6.5M venture capital funding through lead investors Burrill and Co. and Holden Capital |
Conforma Therapeutics Corp. | San Diego | 5/9 | $15 | Conforma raised $15M in a financing led by Forward Ventures, ProQuest Investments, Domain Associates, Lombard Odier and Inglewood Ventures |
Corgentech Inc. | South San Francisco | 5/3 | $13 | Corgentech raised $13M in a Series B financing; InterWest Partners, Alta Partners and JP Morgan Partners participated in the financing |
Gemin X Biotechnologies | Montreal | 5/3 | $12.6 | Gemin raised $12.6M in its second round; Sanderling Venture Partners V LP led the round; also participating were Medical Discoveries Fund Inc., Sofinov Societe Financiere D'Innovation Inc., BioCapital Investments Ltd., MVI Medical Venture Investments Ltd. and the Business Development Bank of Canada |
Genicon Science Corp. | San Diego | 5/2 | $27 | Genicon raised $27M in the round; investors included Audax Ventures, CMEA Life Sciences; GIMV and Radius Ventures |
Innovo Biotechnologies | Galilee, Israel | 5/15 | $0.5 | Innovo received an investment of $500,000 from a group of investors, including ProSeed Capital Holdings and Biocom Investments |
Isogenica Ltd. | Cambridge, UK | 5/16** | US$3 | Isogenica raised US$3M in start-up funding |
Memorec Stoffel GmbH | Cologne, Germany | 5/16 | EUR12.8 (US$11.3) | Memorec received a US$11.3M investments, led by 3i Germany; other investors were KSK Wagniskapital, Nordrhein-Westfalen Fonds, tbg Technologie-Beteiligungs-Gesellschaft, TechnoMedia Kvln and Delbr|ck & Co. Privatbankiers |
Mindsense Biosystems Ltd. | Rehovot, Israel | 5/23** | $2 | Mindsense secured a $2M investment from Future Capital AG |
Molecular Mining Corp. | Kingston, Ontario | 5/23 | US$8 | Molecular Mining raised US$8M in its Series B round of financing led by CDP Sofinov; other investors were Business Development Bank, Philadelphia-based S.R. One Ltd., Cardinal Partners and CMDF Queen's Scientific Breakthrough Fund |
Molecular Reflections Inc. | San Diego | 5/7 | $14.2 | Molecular Reflections raised $14.2M in its Series B financing; $7.2M will be paid to the company up front and another $7M will go to the company as potential milestone payments; investors included Forward Ventures, Oxford Bioscience Partners, ProQuest Investments, Sorrento Ventures and Oxcal Ventures |
Neurotech SA | Evry, France | 5/29 | EUR35 (US$30) | Neurotech raised US$30M in a financing led by Merlin Biosciences and Apax Partners France; other investors were Westdeutsche Landesbank Girozentrale, ABN Amro, AGF Innovation and several existing shareholders |
Novirio Pharmaceuticals Ltd. | Cambridge, Mass. | 5/7 | $44 | Novirio raised $44M in a private equity financing led by CSFB Private Equity; other investors were TVM Techno Venture Management, MPM Capital, Nomura International plc, Novartis BioVentures Ltd., Hanseatic Americas LDC, Biomedical Sciences Investment Fund PTE Ltd., Swiss Life Private Equity Partners Ltd., Banc of America Securities LLC and Swan Private Equity Verwaltungs GmbH |
Point Therapeutics Inc. | Boston | 5/25 | $5.4 | Point raised $5.4M in its Series B funding round |
Rejuvenon Corp. | Houston | 5/2 | $12 | Rejuvenon raised $12M; Novo A/S participated in the funding along with BankInvest, Burrill and Co. and Baylor College of Medicine |
Remedyne Corp. | Goleta, Calif. | 5/30 | $3.2 | Remedyne raised $3.2M in a financing led by several investors; investors included Sutton Ventures Group and Dlloyd Investments Ltd., as well as several individuals |
Strakan Group Ltd. | Galashiels, Scotland | 5/8 | #30.5 (US$43.5) | Strakan raised US$43.5M in a financing that included three institutional investors: LMS Capital, 3I and Warburg Pincus & Co. LLC |
ThromboGenics Ltd. | Dublin, Ireland | 5/10 | $12.8 | ThromboGenics closed the $12.8M financing round with East Hill Advisors LLC |
Xenon Genetics Inc. | Vancouver, British Columbia | 5/4 | $2.6 | Xenon raised $2.6M in its second closing of its mezzanine financing round, bringing the round's total to $47.6M |
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $10.5M |
||||
Company (Symbol)#* | Partner (Country) | Amt. (M) | Triggering Event | Details (Date) |
Alkermes Inc. (ALKS) | Serono SA (Switzerland) | ND | Milestone payment | Alkermes received an undisclosed milestone payment for completing a Phase I trial for rhFSH (5/16) |
Alliance Pharmaceutical Corp. (ALLP) | Baxter Healthcare Corp. | $3 | Investment | Alliance received $3M as part of Baxter's commitment to the development of Oxygent (5/30) |
Exelixis Inc. (EXEL) | Bayer AG (Germany) | ND | Milestone payment | Exelixis received an undisclosed milestone payment for delivery of assays for high-throughput screening (5/21) |
Ibis Therapeutics (division of Isis Pharmaceuticals Inc.; ISIP) | Agouron Pharmaceuticals Inc. | $2.5 | Research milestone payment | Agouron will pay Ibis the milestone payment related to the identification of novel RNA targets and the screening of small molecules for the discovery and development of new drugs as part of the collaboration (5/8) |
ImClone Systems Inc. (IMCL) | Merck KgaA (Germany) | $5 | Milestone payment | ImClone earned a $5M milestone payment related to its Phase II study of IMC-C225 (5/31) |
Maxygen Inc. (MAXY) | Pfizer Inc. | ND | Milestone payment | Maxygen achieved a milestone in its agreement with Pfizer for biochemical manufacturing of a Pfizer product (5/3) |
Milkhaus Laboratory Inc.* | Elan Corp. plc (Ireland) | ND | Equity investment | Elan made an undisclosed second equity investment in Milkhaus (5/17) |
Neurobiological Technologies Inc. (NTII) | Merz & Co. (Germany) | ND | Milestone payment | Neurobiological received a second milestone payment for its delivery of Memantine; it has received $5M in payments over the last six months (5/1) |
Paradigm Genetics Inc. (PDGM) | Bayer AG (Germany) | ND | Milestone payment | Paradigm received undisclosed milestone payments for additional screening assays for Bayer's ultra-high-throughput facility (5/15) |
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
* Denotes privately held company. |
||||
** Denotes the date the item ran in BioWorld International. |
||||
ND = Not disclosed |
||||
